{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:56Z","timestamp":1786988036289,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejca.2023.04.016","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T20:19:28Z","timestamp":1682799568000},"page":"112900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma"],"prefix":"10.1016","volume":"189","author":[{"given":"Oliver John","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kicinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valpione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4548","authenticated-orcid":false,"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria G.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Haydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Meshcheryakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsus J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-153X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2820","authenticated-orcid":false,"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahima","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-2164","authenticated-orcid":false,"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-8959","authenticated-orcid":false,"given":"Mario","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.016_bib1","unstructured":"Ferlay J. Colombet M. Soerjomataram I. et al. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. International Agency for Research on Cancer\/World Health Organization, Lyon;\u00a02018 \u3008https:\/\/gco.iarc.fr\u3009."},{"issue":"2","key":"10.1016\/j.ejca.2023.04.016_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.27616","article-title":"International trends in the incidence of malignant melanoma 1953-2008\u2014are recent generations at higher or lower risk?","volume":"132","author":"Erdmann","year":"2013","journal-title":"Int J cancer"},{"issue":"19","key":"10.1016\/j.ejca.2023.04.016_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ejca.2023.04.016_bib4","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.016_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejca.2023.04.016_bib6","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2023.04.016_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fendo.2018.00472","article-title":"Metformin: focus on melanoma","volume":"9","author":"Jaune","year":"2018","journal-title":"Front Endocrinol"},{"issue":"8","key":"10.1016\/j.ejca.2023.04.016_bib8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jid.2017.03.033","article-title":"Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma","volume":"137","author":"Kim","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2023.04.016_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/2159-8290.CD-11-0280","article-title":"Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A","volume":"2","author":"Martin","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2023.04.016_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12885-015-1515-3","article-title":"Variations of BRAF mutant allele percentage in melanomas","volume":"15","author":"H\u00e9lias-Rodzewicz","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.016_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.04.016_bib12","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Alexander","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.ejca.2023.04.016_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2023.04.016_bib14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/pcmr.12576","article-title":"Metformin monotherapy in melanoma: a pilot, open- label, prospective, and multicentric study indicates no benefit","volume":"30","author":"Montaudi\u00e9","year":"2017","journal-title":"Pigment Cell & Melanoma Res"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.016_bib15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/onco.13761","article-title":"Melatonin and metformin failed to modify the effect of dacarbazine in melanoma","volume":"26","author":"Novik","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2023.04.016_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.04.016_bib17","doi-asserted-by":"crossref","first-page":"9660","DOI":"10.3390\/curroncol29120758","article-title":"Prognostic relevance of type 2 diabetes and metformin treatment in head and neck melanoma: results from a population-based cohort study","volume":"29","author":"Spoerl","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.04.016_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/bjd\/ljac003","article-title":"Association of metformin use and survival in patients with cutaneous melanoma and diabetes","volume":"188","author":"Krakowski","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2023.04.016_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1470-2045(18)30077-9","article-title":"BMI and outcomes in melanoma: more evidence for the obesity paradox","volume":"19","author":"Hayes","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.016_bib20","doi-asserted-by":"crossref","unstructured":"Kennedy O.J., Neary M.T. The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysis. Cancer immunology, immunotherapy: CII. Germany; 2022.","DOI":"10.1007\/s00262-022-03229-x"},{"issue":"3","key":"10.1016\/j.ejca.2023.04.016_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.016_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001117","article-title":"Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study","volume":"8","author":"Rutkowski","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2023.04.016_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2022.10.013","article-title":"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle","volume":"178","author":"Antoun","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:56Z","timestamp":1760733716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"alternative-id":["S0959804923002174"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112900"}}